Fig. 5.
Primary and recall intracellular cytokine responses of CD11chighCD8+ mDCs to α-galactosylceramide C26:0 (α-GalCer) and C20:2. Non-obese diabetic (NOD) mice (4–6 weeks old) were treated with a single dose [4 µg, intraperitoneally (i.p.)] of α-GalCer, C20:2 or vehicle and rested for 1 week to induce invariant natural killer T (iNK T) cell anergy. Mice were then reinjected with the same dose (4 µg, i.p.) of glycolipid. Splenocytes were harvested 6 h after the final injection, cultured in vitro for 3 h in the presence of a protein transport inhibitor, GolgiStop, and CD11chighCD8+ myeloid DCs (mDCs) were stained for intracellular levels of interleukin (IL)-12 and IL-10. Data are representative of two independent experiments yielding similar results; five mice/treatment group. *Significant (P < 0·05) difference between the vehicle/vehicle and glycolipid treatment groups. †Significant (P < 0·05) difference between indicated values.